PTO/SB/08a (01-10)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10681745
Filing Date	2003-10-08
First Named Inventor	Suzie Hwang Pun
Art Unit	1627
Examiner Name	Timothy E. Betton
Attorney Docket Number	T2021-700810/CRP02-002P1R

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	4877778		1989-10-31	Carpenter et al.	
	2	4887778		1989-12-19	Soth et al.	
	3	5276088		1994-01-04	Yoshinga	
	4	5698535		1997-12-16	Geczy et al.	
	5	5728804		1998-03-17	Sharma et al.	
	6	5880154		1999-03-09	Boukrinskaia et al.	
	7	6060597		2000-05-09	Tobe et al.	
	8	6132734		2000-10-17	Thomas et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10681745
	Filing Date	2003-10-08
	First Named Inventor	Suzie Hwang Pun
	Art Unit	1627
	Examiner Name	Timothy E. Betton
	Attorney Docket Number	T2021-700810/CRP02-002P1R

	9	6420176		2002-07-16	Lisziewicz et al.	
	10	6509323		2003-01-21	Davis et al.	
	11	6602707		2003-08-05	Hefeneider et al.	
	12	6667293		2003-12-23	Zhao et al.	
	13	6740643		2004-05-25	Wolf et al.	
	14	7132399		2006-11-07	Hefeneider et al.	

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] ¡	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10681745
	Filing Date	2003-10-08
	First Named Inventor	Suzie Hwang Pun
	Art Unit	1627
	Examiner Name	Timothy E. Betton
	Attorney Docket Number	T2021-700810/CRP02-002P1R

	1	1390479	GB		1975-04-16	Giller et al.		☐
	2	2197720	GB		1988-05-25	National Research Development Corporation		☐
	3	200913B	HU		1990-09-28	Ciklodextrin Kutato Fejlesztoe		☐
	4	199117300	WO		1991-11-14	The Procter and Gamble Company.		☐
	5	199428031	WO		1994-12-08	Cyclolab Ltd.		☐
	6	199609073	WO		1996-28-03	Yui et al.		☐
	7	199847536	WO		1998-10-29	University of Otago		☐
	8	199947172	WO		1999-09-23	Recordati S.A. Chemical and Pharmaceutical Company		☐
	9	200033885	WO		2000-06-15	California Institute of Technology		☐
	10	200040962	WO		2000-07-13	Mirus Corporation		☐
	11	200075162	WO		2000-12-14	Mirus Corporation		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10681745
	Filing Date	2003-10-08
	First Named Inventor	Suzie Hwang Pun
	Art Unit	1627
	Examiner Name	Timothy E. Betton
	Attorney Docket Number	T2021-700810/CRP02-002P1R

	12	200075164	WO		2000-12-14	Mirus Corporation		☐
	13	200137665	WO		2001-05-31	Mirus Corporation		☐
	14	200166601	WO		2001-13-09	Fidia Famaceutici S. P.A.		☐
	15	2002049676	WO		2002-06-27	California Institute of Technology		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1	"Adamantane," in The Merck Index, 11th ed., Merck Research Laboratories, p. 24: No. 140 (1989).	☐
	2	"Amantadine," in The Merck Index, 11th ed., Merck Research Laboratories, p. 60: No. 380 (1989).	☐
	3	Amiel et al., "Association Between Amphiphilic Poly(ethylene oxide) and β-Cyclodextrin Polymers: Aggregation and Phase Separation," Advances in Colloid and Interface Science 79:105-122 (1999).	☐
	4	Amiel et al., "New Associating Polymer Systems Involving Water Soluble β-Cyclodextrin Polymers," Journal of Inclusion Phemomena and Molecular Recognition in Chemistry 25:61-67 (1996).	☐
	5	Boussif et al., "A Versatile Vector for Gene and Oligonucleotide Transfer into Cells in Culture and in vivo: Polyethyleninmine," Proceedings of the National Academy of Sciences 92(16):7297-7301 (1995).	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10681745
	Filing Date	2003-10-08
	First Named Inventor	Suzie Hwang Pun
	Art Unit	1627
	Examiner Name	Timothy E. Betton
	Attorney Docket Number	T2021-700810/CRP02-002P1R

	6	Breslow et al., "Cholesterol Recognition and Binding by Cyclodextrin Dimers," J. Am. Chem. Soc. 118:8495-8496 (1996).	☐
	7	Cserhati, "Charge-Transfer Chromatographic Study of the Complex Formation of Some Anticancer Drugs with γ-Cyclodextrin," Analytical Biochemistry 225:328-332 (1995).	☐
	8	Danysz et al., "Aminoadamantanes as NMDA receptor agonists and antiparkinsonian agents-preclinical studies," Neurosci. Biobehav. Rev., Vol. 21(4), pp. 455-468 (1997).	☐
	9	David et ai, Synthesis of hydrophobically end-capped poly(ethyleneglycol)s with UVabsorbing properties. Macromol. Rapid Commun. Vol. 21(14), pp. 990-993 (2000).	☐
	10	Du et al., "Steric Considerations in Supramoleular Incision of Modified β-Cyclodextrins with Triton X-1 00 and α-Bromonaphthalene," Suprarnolecular Chern., Vol. 7, pp. 209-214 (2005).	☐
	11	Epa et al., "Downregulation of the p75 Neurotrophin Receptor in Tissue Culture and In Vivo, Using β-Cyclodextrin-Adamantane-Oligonucleotide Conjugates," Antisense & Nucleic Acid Drug Development, Vol. 10, pp. 469-478 (2000).	☐
	12	Finsinger et al., "Protective Copolymers for Nonviral Gene Vectors: Synthesis, Vector Characterization and Application in Gene Delivery," Gene Delivery 7:1183-1192 (2000).	☐
	13	Fisher, "A Versatile System for Receptor-Mediated Gene Delivery Permits Increased Entry of DNA into Target Cells, Enhanced Delivery to the Nucleus and Elevated Rates of Transgene Expression," Gene Therapy 7: 1337-1343 (2000).	☐
	14	Gonzalez et al., "New Class of Polymers for the Delivery of Macromolecular Therapeutics. Bioconjugate," Chem., Vol. 10, No.6. pages 1068-1074 (1999).	☐
	15	Gosselet et al., "Association of hydrophobically modified poly (N,N-dimethylacrylamide hydroxyethylmethacrylate) with water soluble β-cyclodextrin polymers," Colloids and Surfaces: A: Physicochemical and Engineering Aspects," Vol. 155, pp. 177-188 (1999).	☐
	16	Husain et al., "Complexation of Doxorubicin with β- and γ-Cyclodextrins," Applied Spectroscopy 46(4):652-658 (1992).	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10681745
	Filing Date	2003-10-08
	First Named Inventor	Suzie Hwang Pun
	Art Unit	1627
	Examiner Name	Timothy E. Betton
	Attorney Docket Number	T2021-700810/CRP02-002P1R

	17	Hwang et al., "Effects of Structure of β-Cyclodextrin-Containing Polymers on Gene Delivery," Bioconjugate Chem 12 (2):280-290 (2001).	☐
	18	Iser et al., "Chenodeoxycholic acid treatment of gallstones A follow-up report and analysis of factors influencing response to therapy," N. Engl. J. Med. Vol. 293(8), pp. 378-383 (1975) (abstract only).	☐
	19	Ooya et al., "Synthesis and Characterization of an Oligopeptide-terminated Polyrotaxane as a Drug Carrier," Polym. Adv. Technol. 11 :642-651 (2000).	☐
	20	Smith et al., "Spectral Characterization of β-Cyclodextrin: Triton X-1 00 Complexes," J. Include. Phen. And Mol. Rec. Chern., Vol. 10, pp. 471-484 (1991).	☐
	21	Szente et al., "Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development," Adv. Drug. Deliv. Rev., pp. 3617-3628 (1999).	☐
	22	Tabushi et al., "Artificial Receptor Recognizing Hydrophobic Carbonyl Compounds," Journal of Organic Chemistry 51 (1 0):1918-1921 (1986).	☐
	23	Tojima et al., "Preparation of an α-Cyclodextrin-Linked Chitosan Derivative via Reductive Amination Strategy," J. Polym. Sci., Part A: Polym. Chem. 36:1965-1968 (1998).	☐
	24	Torchilin et al., "TAT Peptide on the Surface of Liposomes Affords Their Efficient Intracellular Delivery Even at Low Temperature and in the Presence of ametabolic Inhibitors," PNAS 98(15)8786-8791 (2001).	☐
	25	Uekama et al., "Cyclodextrin Drug Carrier Systems," Chem. Rev. 98:2045-2076 (1998).	☐
	26	Weickenmeier and Wenz, "Cyclodextrin sidechain polyesters - synthesis and inclusion of adamantan derivatives," Macromol. Rapid Commun., Vol. 17, pp. 731-736 (1996).	☐
	27	Zanta et al., "In Vitro Gene Delivery to Hepatocytes with Galactosylated Polyethylenimine," Bioconjugate Chem. 8:839-844 (1997).	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10681745
	Filing Date	2003-10-08
	First Named Inventor	Suzie Hwang Pun
	Art Unit	1627
	Examiner Name	Timothy E. Betton
	Attorney Docket Number	T2021-700810/CRP02-002P1R

	28	Zhang et al., "Enthalpic Domination of the Chelate Effect in Cyclodextrin Dimers," J. Am. Chem. Soc. 115:9353-9354 (1993).	☐
	29	European Search Report from EP application no.: 03786526.8 dated September 3, 2010.	☐

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.